Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30474684 | 1.00 | MAPK1 (0.65) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL31532 | 0.81 | MAPK1 (0.65) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL29826707 | 0.81 | MAPK1 (0.65) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL6575737 | 0.80 | CA12 (0.53) | L3MBTL1ALDH1A1CA1CA2CA12 | |
| SCHEMBL29651074 | 0.80 | MAPK1 (0.69) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL29651058 | 0.80 | MAPK1 (0.69) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL70712 | 0.80 | MAPK1 (0.69) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| Hydrochloric Acid SCHEMBL2177614 | 0.79 | MAPK1 (0.62) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL69747 | 0.78 | MAPK1 (1.00) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL64688 | 0.78 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2024212024-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024212907-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| EP-4441033-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118715206-A | Novel HDAC inhibitors and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | MSD K.K. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1600442-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
| US-20050119489-A1 | 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor | BAYER HEALTHCARE AG (DE) | 2005-06-02 | — | — | US | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| EP-1465872-A1 | 4-SULFIDE/SULFOXIDE/SULFONYL-1H-PYRAZOLYL DERIVATIVE COMPOUNDS, FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR | Bayer Pharmaceuticals Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003057674-A1 | 4-SULFIDE / SULFOXIDE / SULFONYL-1H-PYRAZOLYL DERIVATIVE COMPOUNDS, FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
| US-4762848-A | IMMUNE SYSTEM STIMULANTS, CYTOSTATIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-09 | — | — | US | disclosed |
| EP-0194572-A1 | Heterocyclic sulfides, process for their preparation and Medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | MAPK1 2296/4885KDM4E 308/4885L3MBTL1 3127/4885 |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | MAPK1 2657/4885KDM4E 301/4885L3MBTL1 3032/4885 |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | GCK, GCKR, GALK1 | MAPK1 1086/4885KDM4E 2147/4885L3MBTL1 4074/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | MAPK1 2657/4885KDM4E 301/4885L3MBTL1 3032/4885 |
| US-20050119489-A1 | 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor | HTR2C, HTR2A, HTR2B | MAPK1 3825/4885KDM4E 2840/4885L3MBTL1 3309/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | MAPK1 1277/4885KDM4E 992/4885L3MBTL1 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.